Shenlian Biomedical approves overseas investment at shareholder meeting

Shanghai Shen Lian Biomedical Corporation (SSE:688098) announced the resolutions passed at its first extraordinary general meeting of shareholders in 2025. The key resolution, "On the Proposal of Overseas Investment and Related Party Transactions of Wholly-Owned Subsidiaries", was approved. The meeting, held on February 21, 2025, saw participation from shareholders representing 43.7080% of the company's voting shares, with 177,466,091 votes in favor, 488,068 votes against, and 37,001 abstentions. All directors and supervisors attended, and the legal proceedings were confirmed by Guohao Lawyers (Shanghai) as compliant with relevant laws and the company's articles of association. The meeting minutes indicated that related shareholders abstained from voting on the key resolution.